Bio-Rad Laboratories (NYSE:BIO.B) (NYSE:BIO.B) is a global provider of life science research and clinical diagnostic products. Founded in 1952 by David and Ruby Schwartz, the company is headquartered in Hercules, California, and operates in more than 35 countries. Bio-Rad serves academic institutions, biotechnology and pharmaceutical companies, hospitals, and government research organizations around the world.
In its life science segment, Bio-Rad offers a broad portfolio of instruments, reagents and consumables designed to support molecular biology, protein analysis, cell biology, and gene expression studies. Key products include real-time PCR systems, droplet digital PCR platforms, electrophoresis and blotting systems, and a variety of antibodies and detection kits. These tools enable researchers to investigate genetic variation, protein function, and cellular processes with high sensitivity and precision.
The clinical diagnostics division provides quality-control solutions, reagents and instruments for transfusion medicine, diabetes monitoring, and immunology. Bio-Rad’s offerings include blood-typing reagents, molecular diagnostics assays, hemoglobin A1c testing systems and proficiency testing programs. These products help clinical laboratories maintain compliance, improve workflow efficiency, and deliver reliable patient results.
Throughout its history, Bio-Rad has emphasized innovation and customer collaboration. The company’s global footprint spans the Americas, Europe, Asia-Pacific and the Middle East, allowing it to support diverse research and healthcare communities. Under the leadership of President and CEO Norman D. Schwartz, the company continues to invest in research and development to expand its product lines and drive long-term growth in the life science and clinical markets.
